Cost-effectiveness study of nitrate therapy using a decision analysis methodology.
The cost-assessment technology of decision analysis was applied to isosorbide dinitrate (ISDN), the standard therapy for angina; isosorbide mononitrate (ISMO), approved mid-1992; and nitroglycerin patches to measure the effect of economics on clinical practice and administrative choices. The evaluation was conducted to illustrate the utility of this method for decision makers in various sectors of the health care system, including physicians, pharmacy benefit administrators, formulary committees, and manufacturers. Findings indicate that despite a higher unit cost for ISMO, total anticipated treatment costs with this new long-acting nitrate are lower than those associated with ISDN (28%) and nitroglycerin patch (16%) therapy in patients with stable angina, and ISMO requires less dosing titration and is associated with fewer tolerance effects.
College of Pharmacy, University of Rhode Island, Kingston 02881.
E P
EP
Larrat
D000787:Angina Pectoris / Q000188:drug therapy* / Q000401:mortality; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D004333:Drug Administration Routes; D016527:Drug Costs / Q000706:statistics & numerical data*; D006801:Humans; D009566:Nitrates / Q000008:administration & dosage* / Q000191:economics* / Q000627:therapeutic use; D014481:United States / Q000453:epidemiology